inhalation of the volatile gas emitted by the adhesive agent Bond G17. She continued this practice for nine months, consuming from 50 to 100 g of the agent every night from January to the middle of September 1971, when she first noticed weakness of the right leg. A week later she was aware of weakness and numbness of both upper and lower extremities and these symptoms were slowly progressive. She was admitted to our hospital on 11 November 1971. General physical examination was negative. Neurological examination revealed flaccid quadriplegia with moderate to severe muscular atrophies, predominantly in the distal parts of all extremities. HISTOLOGICAL EXAMINATION Biopsied specimens were obtained from the left fibularis brevis muscle in case 1 and 2, and the left quadriceps femoris muscle in case 3. Sural nerve biopsies were performed in case 1 and 2. A small piece of the muscle was fixed in formaldehyde solution, embedded in paraffin, and sections were stained with haematoxylin-eosin (H and E). The second portion was rapidly frozen by dry ice, and used for the demonstration of dihydronicotinamide adenine dinucleotide dehydrogenase, ATP-ase, and acid phosphatase activities. Other sections were stained with modified Gomori's trichrome, H and E, and PAS.
For nerve teasing methods, the tissues were fixed in osmium tetraoxide solution and then immersed in a glycerol-water solution. Other pieces of the nerves were embedded in Epon, and 1 Htm sections were stained with toluidine blue for light microscopic study.
Histological findings of biopsied muscles were as follows: in case 1; the muscle fibres ranged from 10 to 85 ,um with most of the fibres measuring 50 ,um in diameter. There was a mild increase in connective tissue. Approximately 6% of the fibres showed central nuclei. Some fibres showed marked degenerative changes with phagocytosis. Occasionally small groups of the small fibres were seen and atrophic fibres were of histochemical types 1 and 2 (Figs 1, 2) . In case 2 the diameter of the muscle fibres varied from 25 to 90,um. There was no increase in the number of centrally located nuclei and there was a mild increase in connective tissue, but no marked degenerative change. Occasionally a small group of small fibres was seen. Normal distribution of fibres as to the histochemical type was preserved. On electronmicroscopic examination, some fibres showed focal myofibrillar degeneration which consisted of Zstreaming and mitochondrial decrease, with no additional findings in cases 1 and 2. In case 3 the histological findings showed similar changes except for type 2 fibre atrophy as in case 2. Sural nerve biopsies showed normal fibre density and a histogram revealed a bimodal distribution in cases 1 and 2. However, there was slight loss of fibres, especially in the larger fibres. There was axonal degeneration and segmental demyelination, more remarkable in case 1 than in case 2 (Figs 3, 4, 5) .
CHEMICAL ANALYSIS OF ADHESIVE AGENT The adhesive agent Bond G-17 contains 30%/ of gum made from chloroprene, 25% n-hexane, 24% toluene, and 20%Y methyl-ethyl ketone. The vapourized elements of this adhesive agent contained the same amount of n-hexane and toluene by gas-chromatography (Fig.  6) . The adhesive agent Bond G-10 contains 28% n-hexane and 30%4 toluene. The adhesive agent Cemedain Contact contains 18% n-hexane and 43%°t
oluene.
COURSE Three of four cases could be followed up. Case 1, who inhaled a large amount of glue, showed almost complete flaccid paralysis of four extremities. However, the patient improved gradually, was able to walk six months after admission and was discharged with a mild difficulty in walking nine months after admission. Case 2, who inhaled a relatively small amount of glue, showed considerable improvement and returned to her daily life without any difficulty in walking four months after admission. Case 3 improved gradually and was able to walk without any difficulty six months after admission.
DISCUSSION
Weakness and sensory impairment of the extremities developed in seven to 30 months after glue sniffing in these four cases. Their symptoms were slowly progressive up to three months after stopping inhalation, and showed gradual improvement thereafter. Neurological examinations revealed mixed type polyneuropathy, predominantly motor, in these cases.
Initial symptoms developed after inhalation of about 20,000 g of glue, Bond G-17 (about 5,000 g n-hexane and about 5,000 g toluene) in case 1; about 2,000 g of glue, Bond G-17 (about 500 g n-hexane and about 500 g toluene) in case 2; about 10,000 g of glue, Cemedain Contact (about 1,800 g n-hexane and about 4,300 g toluene) in case 3; and about 6,000 g of glue, Bond G-10 (about 1,700 g n-hexane and about 1,800 g toluene) in case 4.
The symptoms in case 1 were the most severe of these four cases, and the symptoms in cases 3 and 4 were more severe than those of case 2 who inhaled less glue. Recovery in cases 1, 3, and 4 was slower than that of case 2. These facts suggest that the severity of symptoms is dependent on the total dose of the inhaled glue. Several authors (Wada et al., 1965; Yamada, 1967; Sobue et al., 1968; Yamamura, 1969; Herskowitz et al., 1971) have described cases with n-hexane polyneuropathy which developed two to six months after exposure to n-hexane. Their patients showed progressive symptoms two to three months after exposure ceased. Initial symptoms included sensory impairment in all extremities of glove and stocking distribution. Our cases revealed mainly motor polyneuropathy, while n-hexane produces mainly mixed or sensory polyneuropathy. This difference between our cases and n-hexane polyneuropathy may be due to the presence of toluene in glue and/or the mode of exposure-that is, the difference between relatively longer inhalation time at lower gas concentrations in n-hexane polyneuropathy compared with a shorter inhalation period for a gas of higher concentration in our cases.
It is known that acute intoxication from toluene causes confusion, excitement, impairment of consciousness, and damage to the liver and haematopoietic organs (Baker and Tichy, 1953) . Satran and Dodson (1963) reported one case of chronic toluene intoxication who showed electroencephalographic abnormality after 10 years of toluene sniffing. Grabski (1961) and Knox and Nelson (1966) first reported a case of long-term toluene inhalation that apparently led to cerebellar degeneration. O'Brien et al. (1971) reported a patient who had hepatorenal damage from toluene inhalation. However, peripheral nerve damage was not reported. Lately, Heuser (1968) reported the first case of polyneuropathy due to toluene sniffing. His patient showed tremor, muscle atrophies, and weakness in the extremities. Fabre et al. (1955) described motor weakness of the lower limbs of dogs after chronic toluene exposure. Matsumoto (1971) reported a decrease of motor nerve conduction velocities in rats after one year's exposure to 200 ppm toluene. Therefore, chronic toluene intoxication may cause peripheral nerve damage.
Though n-hexane had been considered to be chiefly responsible for polyneuropathy, toluene also seems to affect the peripheral nerve as
